GlaxoSmithKline isn’t the only FTSE 100 stock I’ll be watching in February

This pharma giant and another FTSE 100 (INDEXFTSE:UKX) stock report to investors in February. Paul Summers contemplates what may happen.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Scene depicting the City of London, home of the FTSE 100

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 pharmaceutical giant GlaxoSmithKline‘s (LSE: GSK) share price had a very decent 2021, rising almost 20% and easily outpacing the the lead index. It’s had a pretty good start to 2022 too, albeit as a result of Unilever‘s interest in acquiring its consumer healthcare business rather than any news on trading. That’s all set to change when GSK provides the market with Q4 numbers on 9 February.

For me, this definitely makes the company one to watch. It’s not the only top-tier stock I see myself checking in on either.

Bid target

Unilever has ruled out another bid for GSK’s brands. Whether this is actually true, it’s certainly got the market talking about these sleepy giants once again. There’s little doubt the CEOs of both companies, but particularly GSK’s Emma Walmsley, are under pressure to deliver for their owners.

I suspect Walmsley might be willing to do a deal… eventually. I also believe that most shareholders would support this if GSK’s leader promised to return the vast majority of what it receives from the sale back to them. Of course, she may have other ideas.

If Unilever stays quiet over the next few weeks, GSK’s short-term performance will likely depend on whether it’s been able to build on the rebound in sales of non-Covid-19 vaccines seen in Q3. There’s a chance this won’t be the case. The world has been grappling with the Omicron variant over the last few months, after all.

Overall however, I think there are more reasons to be bullish than bearish right now. GlaxoSmithKline’s shares aren’t overpriced at 14 times forecast earnings and come with an expected 53.8p per share total dividend. Yes, the latter is a step down from the 80p holders that have grown accustomed to. However, it still equates to a 3.3% yield. That’s almost identical to that offered by the index as a whole.

Another FTSE 100 stock I’ll be watching

After some early promise, the Barclays (LSE: BARC) share price looks like ending January near where it started. I’m actually a little surprised by this. The possibility of quicker-than-expected interest rate rises should be good news for the financial juggernaut and its peers.

Still, it’s hard to complain if you’re a Barclays shareholder. Despite the resignation of CEO Jeff Staley in November, the shares are 45% up on where they stood this time last year. For perspective, that’s a smaller gain than that achieved by Lloyds (53%) but higher than over at HSBC (27%).

Despite this stellar performance, Barclays shares still trade on a little less than 8 times earnings. That might be deemed cheap given its more diversified business model compared to other banks. A 4.1% yield should also be attractive to income hunters.

I don’t see 2021’s gains being replicated in 2022. Nevertheless, I do think this could prove a decent entry point if final results on 23 February are as good as I expect them to be. Revenue from Barclay’s investment banking arm was already showing great momentum when the company last reported to the market in October. 

Of course, the aforementioned division could become something of a liability if market conditions were to suddenly worsen. So if I was to buy Barclays shares today, I would make a point of also being invested in stocks in more defensive sectors. Oddly enough, GlaxoSmithKline might be an ideal candidate!

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Paul Summers has no position in any of the shares mentioned. The Motley Fool UK has recommended Barclays, GlaxoSmithKline, HSBC Holdings, Lloyds Banking Group, and Unilever. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Asian woman holding a cup of takeaway coffee and folders containing paperwork, on her way into the office
Investing Articles

How I could make a 10% yield for high passive income a reality

Jon Smith explains how he can target high passive income from top-yielding stocks, including one specific example he'd consider.

Read more »

Investing Articles

I’d buy 1,784 shares of this FTSE 100 stock to target £350 of monthly passive income

Muhammad Cheema takes a look at how British American Tobacco shares, with a dividend yield of 10.1%, can generate a…

Read more »

White female supervisor working at an oil rig
Investing Articles

1 ex-FTSE 100 stock that I think will get promoted soon

Jon Smith flags up an energy stock that used to be in the FTSE 100 and currently has strong momentum…

Read more »

Shot of a young Black woman doing some paperwork in a modern office
Investing Articles

With an 8% dividend yield, I think this undervalued FTSE stock is a no-brainer buy

With an impressive yield and good track record of payments, Mark David Hartley is considering adding this promising FTSE share…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

£9,500 in savings? Here’s how I’d try to turn that into £1,809 a month of passive income

Investing a relatively small amount into high-yielding stocks and reinvesting the dividends paid can generate significant passive income over time.

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

Dividend star Legal & General’s share price is still marked down, so should I buy more?

Legal & General’s share price looks very undervalued against its peers. But it pays an 8%+ dividend yield, and has…

Read more »

Investing Articles

Dividend shares: 1 FTSE 100 stock to consider buying for chunky shareholder income

This company’s ‘clean’ dividend record looks attractive to me and I’d consider buying some of the shares to hold long…

Read more »

Investing Articles

3 of my top FTSE 250 stocks to consider buying before April

Buying undervalued UK shares can be a great way to generate long-term wealth. Here, Royston Wild reveals a handful on…

Read more »